Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Amgen to present cancer trial data at ESMO congress

Amgen to present cancer trial data at ESMO congress

6th October 2010

Amgen is to present data from several clinical studies of its forthcoming oncology treatments at the European Society for Medical Oncology (ESMO) congress this month.

The company will attend the Milan event between October 8th and 12th 2010 in order to showcase results from important studies of drugs such as denosumab, Vectibix, Neulasta and Aranesp.

Among the abstracts to be presented at the congress are comparisons of denosumab against zoledronic acid and data from the phase III Vecitbix study Spectrum, as well as updates on pipeline treatments such as AMG 386 and AMG 479.

Dr Willard Dere, senior vice-president and international chief medical officer at Amgen, said the presentations will illustrate the "breadth and diversity" of its cancer drug portfolio.

He added: "Amgen is exploring numerous biologic pathways to develop novel therapies to treat cancer and lessen the side effects of cancer and its treatment."

Earlier this week, the company reported data from two phase III Vectibix trials, demonstrating its efficacy both as a first and second-line treatment.ADNFCR-8000103-ID-800101044-ADNFCR

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.